PROSIEBENSAT1 MED. (PBSFF) Rating Reiterated by Citigroup Inc
PROSIEBENSAT1 MED. (OTCMKTS:PBSFF)‘s stock had its “neutral” rating restated by equities researchers at Citigroup Inc in a note issued to investors on Tuesday, May 9th.
PBSFF has been the topic of several other reports. DZ Bank AG reaffirmed a “sell” rating on shares of PROSIEBENSAT1 MED. in a research report on Wednesday, April 19th. Barclays PLC raised PROSIEBENSAT1 MED. from an “equal weight” rating to an “overweight” rating in a research report on Wednesday, January 25th.
PROSIEBENSAT1 MED. (OTCMKTS:PBSFF) traded up 2.0037% during mid-day trading on Tuesday, hitting $41.7807. 376 shares of the stock traded hands. The firm has a market capitalization of $9.56 billion and a P/E ratio of 21.4811. The company has a 50-day moving average of $43.17 and a 200 day moving average of $40.49. PROSIEBENSAT1 MED. has a 1-year low of $33.70 and a 1-year high of $51.22.
Receive News & Stock Ratings for PROSIEBENSAT1 MED. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROSIEBENSAT1 MED. and related stocks with our FREE daily email newsletter.